H.I.G. Capital to buy BioVectra for $250 mln

Mallinckrodt said Sept. 10 that it agreed to sell BioVectra Inc to H.I.G. Capital for about $250 million. The fixed consideration of $175 million includes an upfront payment of $135 million and a long-term note for $40 million, and contingent payments of up to $75 million. BioVectra is a contract development and manufacturing organization.

DealsNorth AmericaUSHealthcareBriefs